Galera Therapeutics Inc (GRTX.D)
Galera Therapeutics Inc is a biopharmaceutical company listed on OTC Markets under the ticker GRTX. The company focuses on developing small molecule dismutase mimetics designed to enhance the effects of radiotherapy in cancer treatment. Its lead program is tilarginine, which is being evaluated in a Phase 1/2 trial as a pan-inhibitor of nitric oxide synthase for patients with highly resistant forms of breast cancer, including metaplastic breast cancer and other refractory subsets of triple-negative breast cancer. Galera is also developing avasopasem manganese, a small molecule dismutase mimetic being studied for radiotherapy-induced severe oral mucositis in patients with head and neck cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GRTX.D
|
$17.63
|
8.2% Upside
|
Fair
|
—
|
—
|
—
|
Good
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
0.2x
|
17.9x
|
—
|
13.059 M
|
11.854 M
|
0.0%
|
35.8%
|
-65.4
|
—
|
-7.4%
|
